Bacteriophage Therapy Shows Promise in Treating High-Alcohol-Producing Klebsiella pneumoniae-Associated Nonalcoholic Fatty Liver Disease
Researchers have discovered a potential link between a type of bacteria called High-alcohol-producing Klebsiella pneumoniae (HiAlc Kpn) and nonalcoholic fatty liver disease (NAFLD). To further investigate this connection, they conducted a study using HiAlc Kpn-specific bacteriophage therapy on mice with HiAlc Kpn-NAFLD. The results showed promising outcomes, as the treatment successfully reduced hepatic dysfunction and normalized liver inflammation and metabolism. Importantly, the therapy did not have any negative effects on the liver or kidney function. These findings suggest that bacteriophage therapy targeting HiAlc Kpn could be a potential treatment option for NAFLD.